Skip to main content

Table 1 Summary table of the meta-analysis

From: Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis

A) ER

        
 

Country

Study design

Disease

N

Age (range)

Survival analysis

Hazard ratios

Follow-up, months

Athanassiadou 1999 [39]

Greece

R

EC

80

62.7 (48–82)

OS

SC

140

Backe 1997 [54]

German

R

EC

124

68 (30–94)

OS

Reported

57.6 (0.24–180)

Borazjani 1989 [40]

USA

R

EC

44

66 (36–86)

OS

SC

120

Chambers 1988-1 [51]

USA

R

EC

168

OS

DE

24 (1–118.8)

Covens 2011 [45]

USA

P

EC

67

OS, PFS

SC

36

Creasman 1985 [13]

USA

R

EC

168

63 (30–92)

DFS

DE

25 (1–74)

Engelsen 2008 [34]

Norway

R

EC

230

OS

SC

192

Felix 2012 [28]

USA

R

EC

199

OS, RFS

SC

42 (0.8–144)

Fukuda 1998 [14]

Japan

R

EEC

92

60.3 (31–86)

DFS, OS

SC, reported

61.2 (0–174)

Gates 2006 [52]

USA

R

EC

108

64.2 (27–95)

OS

DE

60

Gonzalez-Rodilla 2013 [20]

Spain

R

EC

126

65.9 (43–88)

OS

Report

70

Gul 2010 [31]

Turkey

R

EC

49

58.3 (30–81)

OS

DE

24

Huvila 2013 [61]

Finland

R

EEC

182

67 (35–93)

DFS

Reported

62.8 (4.2–84.4)

Ito 2005 [57]

Japan

R

EEC

103

57

OS

Reported

60 (2–148)

Jongen 2009 [17]

Netherlands

R

EEC

315

64.7 (32–89)

DSS, RFS, OS

SC

59.6 (0–258)

Kadar 1993 [16]

USA

R

EC

137

OS

DE

60

Kamat 2009 [32]

USA

R

EEC

139

63 (27–91)

DSS

Reported

24.9

Kalogiannidis 2008 [35]

Greece

R

EC

77

62.5 (35–80)

OS, CSS, DFS

DE

60 (9–120)

Kauppila 1986 [42]

Finland

R

EC

153

DFS, OS

SC

42 (12–96)

Krakstad 2012-primary [27]

Norway

P

EC

182

DSS

SC

60

Krakstad 2012-prospective [27]

Norway

P

EC

474

DSS

SC

60

Lenhard 2013 [59]

German

P

EC

292

65.1 (35.6–88)

OS

Reported

13.8 (13.1–14.5)

Liao 1986 [43]

USA

R

EC

75

OS

SC

50

Lindahl 1992 [50]

Sweden

R

EC

298

63 (36–87)

OS

DE

60

Martin 1983 [44]

Australia

P

EC

87

(48–85)

OS

SC

(8–68)

Merritt 2010 [55]

USA

R

EEC

85

63.4 (39–91)

DSS

Reported

72

Mhawech-Fauceglia 2013 [48]

USA

R

EC

316

OS

DE

60

Mylonas 2010 [30]

Germany

R

EEC

214

65.1 (35–88)

PFS, CSS, OS

SC

96.3 (0.03–176.8)

Palmer 1988 [41]

Australia

R

EC

351

64.5 (31–89)

OS

SC

100

Pertschuk 1996 [47]

Caucasian, Hispanic, Oriental

R

EC

78

65.5 (38–89)

OS

SC

37.5 (13–161)

Pradhan 2012 [26]

Norwegian

P

UPSC

52

72 (56–89)

OS, PFS

DE

60

Saito 2006 [56]

Japan

R

EEC

103

57

DFS, OS

Reported

60 (2–148)

Rahman 2013 [18]

Japan

R

EEC

111

60 (26–85)

PFS, OS

Reported

52 (5–139)

Salvesen 1998 [58]

Norway

P

EC

97

65 (37–92)

OS

DE

108 (60–180)

Shabani 2007 [36]

Germany

R

EC

293

64.8 (35.5–88)

PFS, CSS, OS

SC

89.6 (3.2–135.5)

Sho 2014 [60]

Japan

R

UPSC

33

69.6 (55–82)

CSS

Reported

29 (2–174)

Singh 2007 [37]

USA

P

EC

48

OS

Reported

19

Sivridis 2001 [38]

Greece

R

EC

164

OS

SC

55 (19–167)

Song 2012 [29]

Korea

R

EC

137

53.7 (30–82)

OS

Reported

60

Sun 2013 [46]

China

P

EC

73

58 (30–78)

DFS

SC

43.4 (16–91)

Voss 2011 [22]

England

P

EC

156

68.2 (37–89)

DSS, RFS

Reported

48.1 (0.1–141.5)

Wik 2013-R [49]

Norway

R

EC

266

DSS

SC

300

Wik 2013-P [49]

Norway

P

EC

153

DSS

SC

300

Zannoni 2013 [25]

Italy

P

EEA

121

59 (35–88)

DFS, OS

Reported

38 (14–91)

Zhang 2013 [53]

China

R

EC

239

54 (26–82)

DFS, OS

DE

67 (12–183)

Zou 2012 [21]

China

R

EEC

60

51.3 (30–72)

OS

Reported

45.5 (3–69.5)

B) PR

        
 

Country

Study design

Disease

N

Age (range)

Survival analysis

Hazard ratios

Follow-up, months

Athanassiadou 1999 [39]

Greece

R

EC

80

62.7 (48–82)

OS

SC

140

Backe 1997 [54]

German

R

EC

197

68 (30–94)

OS

Reported

57.6 (0.2–180)

Borazjani 1989 [40]

USA

R

EC

44

66 (36–86)

OS

SC

120

Chambers 1988-1 [51]

USA

R

EC

168

67 (49–90)

OS

DE

24 (1–118.8)

Creasman 1985 [13]

USA

R

EC

105

63 (30–92)

DFS

DE

25 (1–74)

Ehrlich 1988 [65]

USA

R

EC

174

56 (25–89)

OS

SC

27 (1–152)

Engelsen 2008 [34]

Norway

R

EC

230

OS

Reported

192

Fukuda 1998 [14]

Japan

R

EEC

92

60.3 (31–86)

DFS

SC

61.2 (0–174)

Gates 2006 [52]

USA

R

EC

108

64.2 (27–95)

OS

Report

60

Gonzalez-Rodilla 2013 [20]

Spain

R

EC

126

65.9 (43–88)

OS

Reported

70

Gul 2010 [31]

Turkey

R

EC

49

58.3 (30–81)

OS

DE

24

Huvila 2013 [61]

Finland

R

EEC

182

67 (35–93)

DFS

Reported

62.8 (4.2–84.4)

Ito 2005 [57]

Japan

R

EEC

103

57

DFS, OS

Reported

60 (2–148)

Jongen 2009 [17]

Netherlands

R

EEC

300

64.7 (32.0–89.0)

DSS, RFS, OS

SC, reported

59.6 (0–258)

Kadar 1993 [16]

USA

R

EC

137

OS

DE

60

Kalogiannidis 2008 [35]

Greece

R

EC

77

62.5 (35–80)

OS, CSS, DFS

DE

60 (9–120)

Kamat 2009 [32]

USA

R

EEC

139

63 (27–91)

DSS

report

24.9

Kauppila 1986 [42]

Finland

R

EC

153

DFS, OS

SC

42 (12–96)

Liao 1986 [43]

USA

R

EC

86

 

OS

SC

50

Lenhard 2013 [59]

German

P

EC

292

65.1 (35.6–88.1)

OS

Reported

13.8 (13.1–14.5)

Lindahl 1992 [50]

Sweden

R

EC

272

63 (36–87)

OS

DE

60

Merritt 2010 [55]

USA

R

EEC

85

63.4 (39–91)

DSS

Reported

72

Palmer 1988 [41]

Australia

R

EC

351

64.5 (31–89)

OS

SC

100

Pradhan 2012 [26]

Norwegian

P

SAC

50

72 (56–89)

OS, PFS

DE

60

Rahman 2013 [18]

Japanese

R

EEC

110

60 (26–85)

PFS, OS

Reported

52 (5–139)

Sakaguchi 2004 [62]

Japan

R

EC

120

32–74

OS

SC

60

Saito 2006 [56]

Japan

P

EEC

103

57

DFS, OS

Reported

60 (2–148)

Salvesen 1998 [58]

Norway

P

EC

96

65 (37–92)

OS

Reported

108 (60–180)

Shabani 2007 [36]

Germany

R

EC

293

64.8 (35.5–87.9)

PFS, CSS, OS

SC

89.6 (3.2–135.5)

Singh 2007 [37]

USA

P

EC

49

 

OS

Reported

19

Sivridis 2001 [38]

Greece

R

EC

164

OS

SC

55 (19–167)

Song 2012 [29]

Korea

R

EC

137

53.7 (30–82)

OS

Reported

60

Steiner 2003 [63]

Germany

R

EC

115

65 (38–81)

OS, RFS

SC

72 (36–156)

Sutton 1989 [64]

USA

R

EC

139

61 (31–89)

DFS

SC, DE

28.9 (1–128)

Voss 2011 [22]

England

P

EC

156

68.2 (37–89)

DSS, RFS

Reported

48.1 (0.1–141.5)

Zannoni 2013 [25]

Italy

P

EEC

121

59 (35–88)

DFS, OS

Reported

38 (14–91)

Zhang 2013 [53]

China

R

EC

239

54 (26–82)

DFS, OS, RFS

SC

67 (12–183)

Zou 2012 [21]

China

R

EEC

60

51.3 (30–72)

OS

Reported

45.5 (3–69.5)

C) HER2

        
 

Country

Study design

Disease

N

Age (range)

Survival analysis

Hazard ratios

Follow-up, months

Backe 1997 [54]

German

R

EC

222

68 (30–94)

OS, RFS

SC

57.6 (0.24–180)

Cianciulli 2003 [76]

Italy

R

EC

73

 

OS

SC

72

Coronado 2001 [72]

Spain

R

EC

114

65 (37–85)

PFS

SC

6 (14–107)

Gates 2006 [52]

USA

R

EC

99

64.2 (27–95)

OS

report

60

Gonzalez-Rodilla 2013 [20]

Spain

R

EC

126

65.9 (43–88)

OS

report

70

Jongen 2009-2 [33]

Netherlands

P

EEC

315

64.7 (32–89)

OS, RFS

Reported

59.6 (0–258)

Kohlberger 1996 [73]

Australia

R

EC

100

64 (36–85)

OS

SC

140

Konecny 2009 [68]

USA

R

EC

273

65 (38–90)

OS

SC

EEA83 (0.3–270) USPC20 (0.1–162), CCC38 (0.2–180)

Mori 2010 [67]

Japan

R

EEC

63

57.5 (32–78)

RFS, OS

SC

61.9 (7–133)

Odicino 2008 [69]

Italy

R

USPC

10

positive: 79–84; negative: 57–76

OS

DE

19.7 (1–87)

Peiro 2004 [76]

German

R

EC

10

60 (29–91)

OS

SC, reported

53

Saffari 1995 [74]

Hispanic

R

EC

75

60 (29–87)

OS

SC

144

Santin 2005-1 [70]

USA

R

USPC

27

66 (62–75)

DSS, OS

SC, reported

33 (10–48)

Santin 2005-2 [71]

USA

R

USPC

30

67.5 (63–75)

OS

SC

42 (10–51)

Togami 2012 [66]

Japan

R

UPSC

71

63.6 (47–81)

RFS, OS

Reported

49.7 (4–125)

Voss 2011 [22]

England

P

EC

156

68.2 (37–89)

DSS, RFS

Reported

48.12 (0.12–141.48)

  1. Study design is described as prospective (P) or retrospective (R)
  2. EC endometrial cancer, EEC endometrioid endometrial cancer, UPSC uterine papillary serous carcinoma, OS overall survival, CSS cancer-specific survival, DSS disease-specific survival, PFS progression-free survival, RFS relapse-free survival, DFS disease-free survival, DE data-extrapolated, SC survival curve
  3. not reported
  4. [ ]Reference number